Painchek Ltd · ASX:PCK
Painchek — Investor Presentation (November 2019)
19 slides from Painchek's investor presentation, Nov 28, 2019
Slide 1: Investor Update - November 2019
For personal use only ® Investor Update - November 2019 PainChek Ltd ASX:PCK 1 PainChek™ Commercial in Confidence
Slide 2: Executive Summary
Executive Summary For personal use only § PainChek® provides Software-As-A-Service that utilizes AI for the detection of patient pain via video analysis • Targeting enterprise customers who have patients with an inability to communicate pain levels (e.g. dementia) • Video assessment via mobile app,
Slide 3: PainChek accelerating growth in clients, bed licenses and clinical assessments
PainChek® accelerating growth in clients, bed licenses and clinical assessments For personal use only Contracted number of Residential Contracted Annual Recurring Revenue Residential Aged Care Clients and Aged Care Beds (CNRB) (ARR) (A$m) Facilities Contracted 280 25000 24,170 1.02* Millions 1 250 2
Slide 4: Highlights of PainChek Business and Revenue Model
Highlights of PainChek® Business and Revenue Model For personal use only ü Patent coverage and no direct competition – we have first mover advantage for 15 years+ ü Gross margins in excess of 80% at scale – low cost of goods sold ü Small sales force requirement o Initial enterprise B2B model require
Slide 5: The problem
The problem For personal use only Pain assessment is difficult especially for those who cannot communicate such as dementia sufferers or infants/toddlers. Pain is often under detected. Leading to under treatment and misdiagnosis. This can lead to adverse impact on quality of care, operational effici
Slide 6: Our "Why"
Our “Why” For personal use only Our purpose is to give a voice to people who cannot verbalise their pain 6 PainChek™ Commercial in Confidence
Slide 7: Pain assessment in dementia care is ready for disruption
Pain assessment in dementia care is ready for disruption For personal use only Abbey Pain PainChek® § Abbey Pain Scale (APS) and similar manual systems are the current Scale 2017 standard of care in developed countries for assessment of pain in 2003 dementia patients § Key inputs in the APS rely on
Slide 8: Diversified customer and partners
Diversified customer and partners For personal use only Example Aged Care Customers Advocates & Supporters 8 PainChek™ Commercial in Confidence
Slide 9: Intellectual Property, Patents and Trade Marks
Intellectual Property, Patents and Trade Marks For personal use only 1. Intellectual Property • PainChek has acquired a global, exclusive, perpetual and non-revocable license from nViso Sarl for the nViso Software Development Kit (SDK) and training tools to develop mobile applications in the field o
Slide 10: Integration partners
Integration partners For personal use only • We are integrated with most of the major aged care management systems used by more than 160,000 aged care beds in Australia and 40,000 beds in the UK • Direct integration means data flows automatically into existing systems reducing duplication of data en
Slide 11: Australian Federal Government Support of $5m
Australian Federal Government Support of $5m For personal use only • Aus Federal govt. has pledged $5m for PainChek to implement into Aus residential aged care market • Government is paying for a discounted 12 month subscription for up to 100k aged care beds • Govt wants to aid rapid adoption of Pai
Slide 12: PainChek - Dementia Is A Large Market Opportunity
PainChek® - Dementia Is A Large Market Opportunity For personal use only § 47Million living with dementia globally - estimated to increase to 75 Million by 2025 ENTERPRISE DEMENTIA MARKET VALUE Aus UK US ROW est TOTAL No. Aged Care Beds 0.22m 0.54m 1.7m 4.5m 6.96m Annual Market Value @ A$11m A$26m A
Slide 13: PainChek hospital market opportunity is significant
PainChek® hospital market opportunity is significant For personal use only • Manual pain assessment is a common mandatory task in all hospitals • PainChek can easily integrate into existing hospital patient monitoring systems • It could be used to monitor pain, similar to other key vital signs such
Slide 14: New Product Development: Pre-verbal Children's App
New Product Development: Pre-verbal Children’s App For personal use only • Parents/practitioners have difficulty discerning whether pre-verbal children (0-3 years) are in genuine pain or just crying from discomfort, hungry, wanting attention etc. • We have leveraged the same facial recognition techn
Slide 15: Pipeline Of New Product Launches To Support Growth
Pipeline Of New Product Launches To Support Growth For personal use only § Initial Market entry with Enterprise versions to validate utility with Health Care Professionals (HCP) sector and build value § Direct to Carer (DTC) market expansion when HCP support in place and DTC training materials § 47
Slide 16: Catalysts and Expected Newsflow
Catalysts and Expected Newsflow For personal use only • First revenue from Australian government expected – Q4 2019 • Signing of large well known aged care providers announced – Q4 19 / Q1 20 • Govt contract signed and expansion of Australian customer base – Q4 2019 • First UK sales of Enterprise De
Slide 17: APPENDIX
For personal use only ® APPENDIX 17 PainChek™ Commercial in Confidence
Slide 18: THE TEAM
THE TEAM For personal use only Philip Daffas Prof. Jeff Hughes Mustafa Atee CEO & Managing Director, MBA, BSc Chief Scientific Officer PhD, MPS Research Scientist MPS, PhD (candidate) Philip is a highly accomplished global business Jeff is a professor in the School of Pharmacy, Mustafa is a clinical
Slide 19: THE BOARD
THE BOARD For personal use only John Murray Chairman John Murray Philip Daffas Ross Harricks Adam Davey Non- Exec Chair CEO & Managing Director Non-Exec Director Non-Exec Director 25 years in tech and Venture Capital. Philip is a highly accomplished global Senior global medical device Corporate fina